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Abstract 
Purpose: Monitoring of key markers for lung cancer detection and tracking of acquired drug resistance is critical for 
the management of the disease. We aim to ascertain the value of monitoring both total cell free DNA concentrations 
and mutant EGFR DNA content within diverse groups of individuals most vulnerable to the disease.
Methods: We proposed longitudinal monitoring of circulating DNA using digital PCR. Circulating DNA present in 
peripheral blood can be obtained non-invasively and provide timely disease status update. 25 heavy smokers and 50 
patients undergoing TKI therapy were recruited. Peripheral blood specimens were taken at different time points and 
their circulating DNA were analyzed and quantified.
Results: Significant higher concentrations of total cell free DNA were detected when compared with healthy 
high-risk individuals. Levels were stable throughout the treatment cycles, which makes it potentially a useful tool for 
patient stratification. Concurrent mutant T790M DNA detection of lung cancer patients at baseline achieved 82 % 
concordance with matched tissue analysis. Samples initially negative for the T790M gene mutation that became posi-
tive during treatment were corroborated with a repeat biopsy. The results showed its usefulness for serial monitoring.
Conclusion: Monitoring of circulating DNA addresses the need for disease detection and shows the ability to cap-
ture the dynamic changes of the disease.
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Background
Non small cell lung cancer (NSCLC) is the leading cause 
of cancer death and tyrosine kinase inhibitors (TKIs) 
have emerged as crucial treatment options (Lynch et al. 
2004). However, most patients inevitably show disease 
progression due to several different mechanisms (Seq-
uist et al. 2011). The most common is a single secondary 
mutation in exon 20 of the EGFR gene (T790M; Ohashi 
et al. 2013). As a result of the bulkier methionine residue 
at position 790, it abrogates the inhibitory role of the TKI 
(Pao et  al. 2005). The median time to disease progres-
sion is approximately 12 months (Kobayashi et al. 2005). 
Acquired resistance remains the lethal weakness for the 
use of TKIs and it is meaningful to monitor the emer-
gence of T790M mutation.
In this regard, repeat tissue biopsies can provide criti-
cal information of patients’ current disease status but 
physical constraints such as ill health and reluctance for 
surgery do not allow for longitudinal monitoring. Tumor 
tissues are also heterogeneous (Bedard et al. 2013) which 
is challenging to accurately profile the disease. Liquid 
biopsy via circulating DNA in cancer patients is an attrac-
tive source for tumor analysis as it offers real time moni-
toring with a simple blood draw (Diaz and Bardelli 2014). 
The mutant DNA phenomenon has been extensively 
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investigated for lung cancer in recent years (Watanabe 
et al. 2015; Thress et al. 2015). The DNA is typically frag-
mented and found in the cell free component of whole 
blood. It was initially reported by Mandel and Metais in 
1948 (Mandel and Metais 1948) and is now found to be 
useful in many disciplines of medicine (Papageorgiou 
et al. 2011; Diehl et al. 2008). Isolating circulating DNA 
from individuals may yet be another effective means to 
detect and track cancer.
Here we aim to show individuals at higher risk of lung 
cancer and patients who are on therapy to benefit from 
detecting and tracking circulating DNA. Through con-
current monitoring of cfDNA in blood plasma and meas-
uring the quantity of T790M EGFR mutation that confers 
TKI resistance in patients, we hope to ascertain a detec-
tion routine that will aid to identify high-risk patients. 
Our results showed that cfDNA is stable over time and 
significantly elevated for patients. This presents oppor-
tunities of utilizing cfDNA as a cancer biomarker. Fur-
thermore, longitudinal studies of blood samples provided 
real time monitoring of changes to the disease mutational 
profile.
Methods
Study cohort and trial approvals
50 NSCLC patients undergoing treatment within our 
clinics were recruited for this study as approved by the 
Institutional Review Board (IRB). Patients were on EGFR 
TKI treatment and divided into two groups based on 
their EGFR T790M mutation status. Details are provided 
in Table  1. Tumor genotyping was performed during 
routine clinical care. Baseline blood samples were taken 
within a week after the first dose of TKI. A total of 25 
patients were enlisted in each group and all patients con-
sented to be part of the study. Selected patients whose 
results were discordant with the primary tumor analysis 
after 6 months of monitoring underwent a repeat biopsy 
for confirmation studies. Additionally, 25 healthy volun-
teers who are smokers but had been tested to be disease 
free were recruited as well. Healthy volunteers under-
went a detailed clinical examination and/or radiographic 
imaging to confirm their disease free status.
Plasma sample processing
Peripheral blood was collected from each patient dur-
ing follow-up visits. Blood samples were drawn in 10 ml 
EDTA vacutainers and processed within 2 h. The process 
was the same for healthy volunteer’s blood sampling. 
Plasma extraction was performed by centrifuging the 
blood samples at 1000g for 10 min at 4 °C and the super-
natant carefully transferred into a separate collection 
tube. A repeat centrifugation step was performed on the 
supernatant to remove any remaining cells. cfDNA was 
extracted from these samples using Qiagen’s QIAamp 
Circulating Nucleic Acid kit (Qiagen Inc., USA) follow-
ing manufacturer’s instructions. Approximately 5  ml 
of plasma were processed from each sample and stored 
at −20  °C prior to molecular analysis. Blood specimens 
from the healthy volunteers were also subjected to the 
same processing steps.
Detection of mutant EGFR, T790M via ddPCR
Droplet digital PCR (ddPCR) was done on a QX100 
ddPCR system (BioRad, USA). The assay provides the 
sensitivity to detect low levels of mutant target DNA in 
each sample. Primers and probes for T790M detection 
were adopted from Oxnard et al. (2014). cfDNA extracted 
Table 1 Patients suffering from  NSCLC and  on TKI treat-
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from the blood samples were analyzed for T790M muta-
tion at each sampling time point. Validation runs with 
control specimens were prepared using plasmids con-
taining T790M and wild type EGFR.
Measurement of cell free DNA quantity
Total cfDNA after extraction was quantified using Quant-
iT™ PicoGreen® dsDNA Assay Kit (ThermoFisher, USA) 
following manufacturer’s instructions. Briefly, the Pico-
Green reagent was freshly prepared and each reaction 
contained 50  μl of working solution and sample DNA. 
Every sample was examined in duplicates. Measurements 
were taken on a fluorometer (Tecan, USA) at wavelengths 
of 520 nm (emission) and 480 nm (excitation). Standard 
curves were produced with Lambda DNA by serial dilu-
tion. The average values of two replicates were taken as 
the final measurement.
Statistical analysis
In order to analyze the correlation between patients’ 
mutant DNA in blood and that of the tissue biopsies, 
the Cohen’s kappa was used to deduce the significance 
between the two variables. Comparisons of cfDNA in 
healthy volunteers’ and patients’ specimens were done 
using the Student’s t test. A receiver-operating curve 
(ROC) was plotted for healthy volunteers against patients 
with lung cancer to evaluate the suitability of cfDNA 
analysis as a detection assay. Survival analysis was per-
formed with the Kaplan–Meier estimate and the overall 
survival (OS) of patients was compared using the log-
rank test. All categorical variables were represented as 
mean  ±  standard deviation unless otherwise specified. 
All statistical analyses were calculated using the Prism 
software (GraphPad, San Diego, USA).
Results
Study design and detection assay characteristics
Our study is a systematic analysis to investigate the 
potential utility of circulating DNA in three critical 
cohorts. We compared lung cancer patients receiving 
EGFR-TKI treatment (Fig. 1a) with high-risk healthy vol-
unteers who are smokers with more than 20 pack-years. 
Patients who had advanced or recurrent NSCLC were 
divided into two main groups, one with the drug resist-
ance mutation T790M and the other group lacking this 
mutation. Molecular profiling was done using tissue 
biopsies when the patients were first diagnosed. Periph-
eral blood samples were collected at specific time points 
during patient follow-ups. A second blood sampling of 
healthy volunteers was done after 6 months from the ini-
tial draw. All patients were on TKI treatment of either 
gefitinib or erlotinib for the duration of the study. Details 
of patient characteristics are provided in Table 1. During 
each sampling, both total cfDNA and copies of mutant 
DNA were measured. At the end of the study, patients 
with discordant data from their initial baseline results 
underwent a repeat biopsy for confirmation.
In order to track copies of T790M DNA, we utilized 
a ddPCR assay, which has the sensitivity to detect low 
numbers of target mutant DNA in a pool of wildtype 
background. This is critical as the prevalence of mutant 
DNA in total cell free plasma can be very low (Watanabe 
et  al. 2015). We designed controlled experiments with 
spiked inputs per 25 μl reactions as shown in Fig. 1b to 
validate the assay. Every input condition was repeated ten 
times to ensure the specificity and sensitivity. Our valida-
tions demonstrated good linearity at differing amounts of 
target DNA inputs. Linear regression of the data points 
showed a r2 value of 0.98. The mean detected copies of 
mutant DNA was close to the spiked input amount dem-
onstrating excellent sensitivity. In a background of 1000–
50,000 wildtype copies, the assay successfully picked up 
the mutant DNA. Concentrations as low as 50 mutant 
to 50,000 wildtype copies were used and the results were 
consistent at different background conditions.
Circulating DNA of study cohorts at baseline
The plasma DNA for healthy volunteers and the two 
groups of patients were assessed at the start of the study 
to determine the initial concordance rate. For group 1 
patients that had negative T790M status from tissue 
analyses, three (patients #5, #9 and #10) were found to 
harbor the resistance mutation from blood sampling. 
Samples were analyzed in replicates and both tests were 
positive. Overall the concordance rate for group 1 was 
88 % as shown in Fig. 2a. Group 2 patients with T790M 
positive profiles were found to have six discordant cases 
(patients #28, #32, #33, #37, #41, #42). 76 % of the sam-
ples from ctDNA were established to be in agreement 
with the primary tissue analysis. Collectively, 82 % of all 
samples had concordant genotypes when compared to 
their respective primary biopsies’ results (Cohen’s kappa, 
κ = 0.64, Additional file 1: Figure S1A). All healthy volun-
teers were tested negative for the mutant gene (data not 
shown). Mutant DNA quantities assessed by ddPCR are 
compiled in Fig.  2b. The range of DNA concentrations 
vary between 5 and 95 copies/ml and mean detection was 
46.6 ±  26.9 copies/ml for patients with positive T790M 
genotypes.
Concurrently, quantities of total cfDNA extracted from 
different study groups were compared. We found a sta-
tistical significance of higher total cfDNA for patient 
samples as compared to healthy volunteers with a p 
value <0.0001 as shown in Fig.  2c. However, it was sta-
tistically indeterminate between group 1 and group 2 
patient cohorts. Average recovered cfDNA from healthy 
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volunteers was 2.24 ± 1.50 ng/ml and patient specimens 
yielding 5.03 ± 2.44 ng/ml. For the three positive patients 
in group 1, total cell free DNA quantities were 9.0 (#5), 
2.6 (#9) and 4.4 (#10) ng/ml. Except for patient #5 whose 
total cell free DNA concentration was above the 75th 
percentile of the group, patients #9 and #10 were closer 
to the 25th and 50th percentile respectively.
The area under the ROC for healthy volunteers against 
the 50 lung cancer patients was 0.84 (95 % CI 0.74–0.94) 
as shown in Fig.  2d. For healthy volunteers comparing 
with group 1 patients, the area was 0.83 (95 % CI 0.72–
0.95) and comparing with group 2 patients, the area was 
0.85 (95  % CI 0.7388–0.9524) (Additional file  1: Figures 
S1B and S1C).
Longitudinal monitoring of circulating DNA
In this current prospective study, we examined the circu-
lating DNA of patients undergoing treatment and varia-
tions of healthy volunteers over an extended time period. 
In group 1, four additional patients were observed to have 
a positive mutant EGFR detection besides patients #5, #9 
and #10 who were detected at baseline (Fig. 3a). Patient 
#15 was identified at the second follow-up roughly 
4  months after the first blood test, while patients #19, 
#20 and #21 were detected after 6 months. Interestingly, 
we also observed patient #5 having a sharp increase in 
mutant DNA concentration after 4  months while con-
centrations for patients #9 and #10 remained constant 
throughout. All other specimens were not detected for 
the mutant DNA during the entire serial monitoring 
period.
For group 2 (Fig. 3b), two participants died before the 
completion of the trial and serial data points were lack-
ing (highlighted by the regions in the blue boxes). Of the 
initial six patients that had discordant results, only patient 
#41 was positively identified after 6 months. Excluding the 
two datasets that were incomplete, nine patients showed 
an overall decrease in mutant DNA after 6 months while 
five remained relatively unchanged when compared to 
their respective baseline measurements. Unlike group 
1 patients, we did not observe any cases with large vari-
ations of detected mutant EGFR copies. Similar obser-
vations were also seen in total cfDNA concentrations 
as noted in Fig. 3c. Specimen #13 from group 1 showed 
the largest change with a two-fold reduction compar-
ing the results at 2 and 4 months. Variations in the entire 
study cohort ranges from 0.2 to 5.7 ng/ml. Total cfDNA 
quantities within healthy volunteers (Additional file  1: 
Figure S2) were stable as well. We were able to obtain 
blood specimens from 23 of 25 patients with an average 
Fig. 1 Clinical monitoring of circulating DNA in NSCLC patients. a Clinical specimen characteristics and follow up measurement schedules. b Assay 
sensitivity to detect minute quantities of mutant copies via ddPCR
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concentration of 1.77  ng/ml, a marginal decline from 
2.24 ng/ml at baseline. The average change in concentra-
tion for the measured 23 volunteers was 0.59 ng/ml.
In addition, OS was assessed in group 1 and 2 patients 
to compare their survival outcomes. As shown in Addi-
tional file 1: Figure S3, patients who initially had mutant 
EGFR copies had a worse outcome. Hazard ratio was 
determined to be 3.25 with p value <0.001 using a log 
rank test.
Repeat biopsies confirm ctDNA derived genotypes
Patients identified during the monitoring phase with 
discordant mutant EGFR results with their initial tissue 
diagnosis underwent a repeat biopsy as part of the study. 
The results are highlighted in Fig. 4. Patients #5, #9 and 
#10, which were detected during baseline measurements 
using blood plasma were positive in the following repeat 
biopsy. Patients #15, #19, #20 and #21 that were subse-
quently identified during the course of monitoring were 
positive as well. Overall all group 1 patients who were 
identified during the monitoring period were concordant 
with the final repeat biopsy. However, discrepancies were 
seen in patients #28 and #37 from group 2. Initial and 
repeat biopsies were positive for the resistance mutation 
but negative in all mutant DNA samples.
Discussion
Our study was designed to determine the utility of cir-
culating DNA for clinical oncology especially for early 
detection and monitoring of lung cancer. Prior stud-
ies had focused much attention on patients in different 
stages of the disease (Douillard et  al. 2014; Kim et  al. 
2013; Xie et al. 2004; Leon et al. 1977), and our work has 
further extended to various critical groups. We designed 
Fig. 2 Profiles of NSCLC patients’ circulating DNA quantity taken at baseline. a Concordance measurement of mutant EGFR status using both tissue 
biopsies and ctDNA analysis. b Quantity of T790M mutant DNA across different patient samples. c cfDNA levels measured across different patients 
comparing with healthy volunteers. d ROC analysis for healthy volunteers against lung cancer patients
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the investigation to target high-risk individuals and 
patients resistant to EGFR-TKI therapy, which is one of 
the most prevalent complications for managing the dis-
ease. The incidence of EGFR mutations is estimated at 
around 77 % among NSCLC clinical responders to gefi-
tinib or erlotinib (Sharma et  al. 2007) and the T790M 
mutation alone accounts for 50 % of all cases. It is thus 
important that patients are closely monitored for aber-
rations to the gene. Our studies uncovered several inter-
esting findings. Notably, total cfDNA is useful at baseline 
examination to identify potential cancer patients. In 
addition, the changes in mutant DNA status can be a 
clear indication of secondary EGFR mutations evolving 
in tumors. Consequently, we strongly believe both total 
cfDNA quantities and its mutational signatures may both 
be exploited for diagnostics and monitoring purposes.
Our measurements of cfDNA in healthy volunteers 
as well as NSCLC patients showed several trends. Varia-
tions of cfDNA quantity were small across different groups 
throughout the monitoring period. Furthermore, NSCLC 
patients were shown to have consistently higher absolute 
amounts above healthy volunteers. This suggest the levels 
of total cfDNA is stable at different time points and the 
significantly elevated amounts associated with NSCLC 
patients advocates its use for early detection of the disease. 
A recent study (Szpechcinski et al. 2015) was determined 
to be 90 % sensitive and 80.5 % specific for cancer patients 
comparing with a normal person’s plasma, which concurs 
with our results. We further showed that heavy smokers 
who are of greater risk to lung cancer have two fold lesser 
concentration of cfDNA than patients undergoing TKI 
treatment. ROC analysis showed good accuracy with an 
Fig. 3 Serial monitoring of circulating DNA in the plasma during the treatment process. a Patient group that did not harbor T790M at baseline. 7 
samples indicated the presence of T790M with ctDNA analysis at the end of 6 months. b Patient group that harbored T790M at baseline. Patients 
29 and 32 died before the end of the study and specific data points cannot be obtained. 2 samples indicated the absence of T790M mutations in 
ctDNA. c cfDNA serial measurements for the 2 groups of patients for disease monitoring
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area larger than 0.8 for employing such a test. In addition, 
we observed that total cfDNA quantity did not change sig-
nificantly with increase in mutant DNA amounts as shown 
by patients #5 and #15. We also did not observe any sig-
nificant trends within the two study groups although most 
patients in group 1 responded well to treatment. Our 
results are consistent with several other studies that meas-
ured the effects of total cfDNA concentrations. Gautschi 
et al. (2004) and Tissot et al. (2015) both measured its vari-
ation post chemotherapy and discovered no association 
to therapy. Taken together, the stability of cfDNA con-
centration as measured in our longitudinal study and the 
significantly lower amounts detected in healthy volunteers 
showed that cfDNA can be a potentially useful parameter 
for early detection of lung cancer.
With the concurrent mutant EGFR DNA detection, 
we yielded good concordance with the primary tis-
sue analysis. This is coherent with published literature 
(Watanabe et  al. 2015; Sundaresan et  al. 2015; Oxnard 
et  al. 2014) where efforts have been made to find suit-
able non-invasive methods for monitoring T790M 
mutations. Using similar ultra sensitive methods involv-
ing ddPCR, Masaru et al. identified the mutant gene in 
79.9 % of samples (Watanabe et al. 2015), which is simi-
lar to our results at 76 % for group 2 patients. Addition-
ally, we found it was useful to target samples that did 
not present the mutant gene from tissue biopsies. In our 
analysis of baseline measurements on group 1 cohort, 
we uncovered three patients with positive detection that 
were subsequently verified in the repeat biopsies as true 
Fig. 4 Concordance measurement of selected samples with repeat biopsies performed. a Summary of different patient profiles. b Detailed meas-
urements of mutant DNA concentrations during monitoring
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positives. This is likely the result of intra-tumoral het-
erogeneity (Gerlinger et al. 2012) where the position of 
tissue sampling matters. Current liquid biopsy methods 
shown in this study can further complement existing 
guidelines to better gain an accurate diagnosis of the 
patient’s disease profile.
The main benefits of employing liquid biopsy to man-
age cancer are the ease and non-invasiveness of the 
technique while gaining real time status of how the dis-
ease is evolving. Traditional core needle biopsies are an 
invasive procedure that requires a skilled personal. Fur-
thermore, there are possibilities that inadequate tissues 
are taken or conditions of the patients do not allow for a 
biopsy (Kim et al. 2011). In a study conducted by Sund-
aresan et  al. (2015), 23  % of patients failed to recover 
sufficient material for genotyping. Our study will aid 
such cases and we have shown that this is helpful in a 
number of group 1 patients. Patients #15, #19, #20 and 
#21 were detected at various stages of their treatment 
regime, which were corroborated with the final repeat 
biopsies. Survival analysis of group 1 and 2 patients 
highlighted a worse outcome for patients with mutant 
copies. It is therefore important for constant monitor-
ing to detect changes promptly. The early detection of 
the changes in the gene will allow for quicker clinical 
invention and permit better-tailored treatments as the 
disease evolves. The monitoring regime coupled with 
prompt clinical intervention, such as switching to 3rd 
generation TKIs, will hopefully impact clinical out-
comes in the future.
In summary, our data suggest that clinical monitoring 
using circulating free DNA is beneficial for lung cancer 
patients both in terms of early detection and monitor-
ing of drug response for acquired resistance. Blood 
sampling is a commonly performed procedure that is 
relatively non-invasive and can be used to actively moni-
tor cancer patients. Our study demonstrated that detect-
ing mutant DNA can aid to discover changes within the 
disease much faster and has immediate clinical utility. 
This work focused on various groups most vulnerable 
to the disease. More importantly, we were able to track 
its dynamic changes. Within this dataset of 75 individu-
als, we showed that concentrations of total cfDNA were 
relatively stable throughout the treatment process and 
remained elevated above high-risk healthy individuals. 
This strongly suggests the potential as a diagnostic tool 
and will have to be validated thoroughly with a larger 
cohort study. A future potential study will also include 
clinical invention upon detecting the mutant DNA to 
address clinical outcomes. The methods and procedures 
we have highlighted in this study will better elucidate the 
dynamic nature of cancer during the detection and treat-
ment process.
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